As accumulation of tumor-associated CD11b+ cells with some features of the M2 phenotype was reduced by CsA treatment, we determined if CsA and FK506 (similarly acting drug, more effectively crossing the blood brain barrier) would affect tumor growth. The gene discussed is ITGAM; the disease is neoplasm.